In this study, patients with recurrent GBM were treated with intravenous administration of siBcl2L12-SNAs revealing remarkable gold enrichment in the tumor-associated endothelium, macrophages, and tumor cells, as well as reduction in tumor-associated Bcl2L12 protein expression [83••]. This evidence concerns the gene BCL2L12 and glioblastoma.